Optus Pharma: Strong Q1 Earnings, New Plant Expansion and License Deal on Track

Q1 2026 revenue of KRW 23.2bn (+24% YoY), operating profit of KRW 2.9bn, net profit of KRW 2.5bn (vs. KRW 1.2bn), showing significant improvement.
Disposal of 575,600 treasury shares (approx. KRW 4bn) completed via block trade; remaining 274,385 shares unsold due to buyer default.
Credit rating maintained at A0 (NICE); debt ratio of 12.4%, very sound financials.
Exclusive domestic license for presbyopia treatment QLOSI (from Orasis, signed Sep 2024); preparing for NDA submission.
Second plant construction in Osong on track (completion by end-2026), expanding capacity from 475mn units to 836mn units annually.
Third-party rights offering of KRW 9.99bn completed in Nov 2025; funds partially used for R&D and working capital.
Two pending lawsuits (KRW 200mn compensation claim, KRW 300mn patent infringement); outcome uncertain.
Dividends suspended for 2024-2025 due to facility investments; potential resumption later.